読み込み中
NASDAQHealthcareDrug Manufacturers - General
最新データ
$151.17
+$4.07 · +2.77%
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
前日終値
$151.17
+$4.07 · +2.77%
日中の時刻はETです。市場データは遅延する場合があります。
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
日中レンジ
現在 $151.17
52週レンジ
現在 $151.17
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
96
大幅な割安
センチメント
66
強気
リスク
26
中程度のリスク
モメンタム
44
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
日中レンジ
現在 $151.17
52週レンジ
現在 $151.17
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$151.57
上昇余地（0.26%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2013年1月28日 | 2:1 | — | — |
株式分割 | 2007年6月25日 | 2:1 | — | — |
株式分割 | 2004年9月7日 | 2:1 | — | — |
株式分割 | 2002年3月8日 | 2:1 | — | — |
株式分割 | 2001年2月22日 | 2:1 | — | — |
発効済み 2013年1月28日
2:1
発効済み 2007年6月25日
2:1
発効済み 2004年9月7日
2:1
発効済み 2002年3月8日
2:1
発効済み 2001年2月22日
2:1
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T3528.83億0.27%129.35兆 JPY0.09%￥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI57.75億0.25%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO48.27億0.27%1.8兆 USD0.03%$715.59+0.61%
Invesco QQQ Trust, Series 1QQQ39.1億0.77%5060.67億 USD0.18%$751.27+0.49%
iShares Core S&P 500 ETFIVV24.25億0.27%8964.4億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY22.29億0.27%8172億 USD0.09%$778.57+0.60%
Vanguard Morningstar Value ETFVTV17.37億0.66%2624億 USD0.03%$220.59+0.44%
State Street Health Care Select Sector SPDR ETFXLV12.99億2.98%435.37億 USD0.08%$170.81+1.58%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOInvesco QQQ Trust, Series 1QQQiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
